Intervention not reported
Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Diarrhoea compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.44 [1.74, 3.43]
8 studies · 3788 participants
Low
OR 6.24 [2.79, 13.98]
4 studies · 1670 participants
Moderate
OR 1.8 [1.22, 2.65]
4 studies · 2118 participants
Moderate
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low
Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Infections (All) compared with no bortezomib (moderate certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
1 finding from 1 review
no estimate extracted
82 participants
GRADE not reported
Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders compared with no bortezomib (high certainty).
2 findings from 1 review
Adverse Events: Peripheral Neuropathy · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Peripheral Neuropathy compared with no bortezomib (moderate certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).
1 finding from 1 review
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).
1 finding from 1 review